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Background: Though potentially linked to the basic physiology of stress response we still have no clear
understanding of Gulf War Illness (GWI), a debilitating condition presenting complex immune, endocrine and
neurological symptoms. Here we compared male (n = 20) and female (n = 10) veterans with GWI separately against
their healthy counterparts (n = 21 male, n = 9 female) as well as subjects with chronic fatigue syndrome/ myalgic
encephalomyelitis (CFS/ME) (n = 12 male, n = 10 female).
Methods: Subjects were assessed using a Graded eXercise Test (GXT) with blood drawn prior to exercise, at peak
effort (VO2 max) and 4-hours post exercise. Using chemiluminescent imaging we measured the concentrations of
IL-1a, 1b, 2, 4, 5, 6, 8, 10, 12 (p70), 13, 15, 17 and 23, IFNγ, TNFα and TNFβ in plasma samples from each phase of
exercise. Linear classification models were constructed using stepwise variable selection to identify cytokine
co-expression patterns characteristic of each subject group.
Results: Classification accuracies in excess of 80% were obtained using between 2 and 5 cytokine markers.
Common to both GWI and CFS, IL-10 and IL-23 expression contributed in an illness and time-dependent manner,
accompanied in male subjects by NK and Th1 markers IL-12, IL-15, IL-2 and IFNγ. In female GWI and CFS subjects
IL-10 was again identified as a delineator but this time in the context of IL-17 and Th2 markers IL-4 and IL-5.
Exercise response also differed between sexes: male GWI subjects presented characteristic cytokine signatures at
rest but not at peak effort whereas the opposite was true for female subjects.
Conclusions: Though individual markers varied, results collectively supported involvement of the IL-23/Th17/IL-17
axis in the delineation of GWI and CFS in a sex-specific way.
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An alarming number of Gulf War veterans returning
from Operation Desert Storm have since been afflicted
with a complex constellation of symptoms including
debilitating fatigue, musculoskeletal discomfort, skin
rashes, and cognitive dysfunction [1-3]. We still have no
clear understanding of Gulf War Syndrome (GWS), also
called Gulf War Illness (GWI), although evidence is
mounting of immunological dysfunction in this popula-
tion that may be potentiated by response to stress* Correspondence: gordon.broderick@ualberta.ca
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reproduction in any medium, provided the orwhether psychological, chemical or other. Indeed clinical
presentation of GWS overlaps strongly with that of an-
other stress-mediated illness: Chronic Fatigue Syndrome/
myalgic encephalomyelitis (CFS/ME) [4,5]. Dysregulation
of the hypothalamic-pituitary-adrenal (HPA) axis has been
linked to the pathophysiology of GWI [6-8] and CFS [9].
Associated pathophysiology includes hypersensitivity of
normal cytokine feedback to the HPA axis [10] as well as
the expected stress-induced release of neuropeptides such
as NPY and its mediation of innate immune response and
cortisol levels [11].
Changes within the immune signaling network have
also been observed. In recent work, female adolescent
CFS patients (n = 67 females; age 15 ± 1.4 years) showed
a distinct immune profile when compared to acutelyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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creased production of anti-inflammatory cytokines IL-10,
decreased IFNγ /IL-10 ratio and reduced production of
pro-inflammatory cytokines IL-6, and TNFα in response
to lipopolysaccaride (LPS) challenge in vitro [12]. Also
suggesting an anti-inflammatory polarity in CFS, Skowera
et al. (2004) [13] reported relatively high levels of intracel-
lular IL-4 and IL-10 following in vitro polyclonal stimula-
tion of whole blood from a mixed population of males and
females (n = 13 males and 22 females; age 39 ± 2.1 years
[19–62 years]). Bedoui, et al. (2003) [14] demonstrated
that NPY, a neuropeptide found at elevated levels in fe-
male CFS patients [15] (n = 93 females; age 44 ± 0.9 years
[18–60 years]), suppressed IFNγ production in Th-1 cells
and increased production of IL-4 by Th2 cells. Previous
work by our group in unstimulated peripheral blood
plasma from a cohort of female subjects (n = 40, age 53 ±
1.8 years) also pointed to attenuated Th-1 and Th-17 im-
mune responses in CFS with high Th-2 marker expression
[16]. In contrast Moss et al. (1999) [17] reported elevated
levels of TNFα in serum from CFS subjects in a mixed
group of male and female subjects spanning a broad range
of ages (n = 164 females and 76 males; median age 47 years
[24–76 years]). Similarly Gaab et al. (2005) [18] (n = 10
male and 11 female; age 36 years [30–47 years]) observed a
positive correlation between fatigue and LPS-induced
in vitro production of TNFα in CFS and with IL-6 in both
CFS and control subjects though expression levels were
found to be comparable. Furthermore Carlo-Stella et al.
(2006) [19] investigated cytokine gene polymorphisms and
found significant differences in TNFα and IFNγ genotypes
in CFS subjects suggesting that they might be genetically
predisposed to differences in inflammatory response.
In contrast to CFS, studies of immune response in
GWI subjects have aligned with specific exposure
models and have been conducted in cohorts that were
either exclusively or predominantly male. Though Rook
and Zumla (1997) [20] initially postulated a Th-2 shift
potentially arising from multiple vaccines, as a charac-
teristic immune signature in this population, this was
not substantiated by Zhang et al. (1999) [21]. The latter
found evidence of a type I response with significant up-
regulation of RNA transcript for IL-2 and IFNγ but not
IL-4 nor IL-6 in a mixed population of male and female
CFS veterans (n = 32 male, 11 female veterans; age 36
[20- over 50]). Similarly Skowera et al. (2004) [22] also
reported a low-grade, ongoing immune activation with
the characteristics of a Th-1 type response in a mixed
cohort (n = 40) of male and female veterans with multi-
symptom illness, in particular elevated intracellular
levels of IL-2 and IFNγ as well as anti-inflammatory
cytokine IL-10 following in vitro polyclonal stimulation
of whole blood when correcting for age, sex and vaccin-
ation status. In a subsequent exploration of vaccinationeffects, Allen et al. (2006) [23] found an approximately
equal mix of Th-1 (IFNγ and IL-2) and Th-2 (predomin-
antly IL-13) recall response to anthrax vaccine, whereas
response to plague was polarized toward Th-1 in male
GW veterans (n = 17; age 39 ± 2.5 years). Along these
same lines Brimacombe et al. (2002) [24] concluded that
while Th-1 makers described CFS status in Gulf War
veterans, a Th-2 response factor exerts an effect on cog-
nitive function in this population. A mixed Th-1:Th-2
immune status is also consistent with our recent work in
a small cohort of male subjects (n = 11, age 43 ± 2.1
years [30–55 years]) where we found higher response to
PHA stimulation in GWI subjects for TNFα at rest as
well as in IL-5 and IFNγ during the course of a maximal
exercise challenge [25]. Indeed in a broad review of this
literature and epidemiological findings, Peakman et al.,
(2006) [26] did not find evidence to support a dominant
polarization towards Th-2 immune status alone in symp-
tomatic GW veterans.
There is a growing body of evidence supporting a sig-
nificant role for factors produced by the nervous and
endocrine systems in altering immune cell function [27].
On this basis we hypothesize that lack of agreement in
the above mentioned studies of cytokine signatures in
these illnesses may be linked at least in part to sex-
specific differences in endocrine-immune cross-talk that
are also illness-specific. Preliminary work by our group
using an exercise paradigm in a pilot-scale cohort of
male GWI subjects (n = 10 training set, 16 validation set,
age 42 ± 1.2 [33–58 years]) indicated noticeable gender
and illness-specific differences in an abbreviated panel of
plasma and PHA-stimulated cytokines with levels found
in male CFS subjects (n = 9, age 42 ± 2.8 [28–56 years]),
and female GWI subjects (n = 10, 47 ± 2.0 [38–58 years])
[28]. Indeed a large number of existing studies have been
carried out in cohorts that consist of either male or fe-
male subjects. Though both sexes have been used in
some of these studies, notably Skowera et al. (2004) [22],
they have not for the most part been compared directly.
In addition work like that of Skowera et al. (2004) [22]
typically profiled a very focused subset of Th-1 and/or
Th-2 cytokines. In this work we have extended the work
of Skowera et al. in two ways. First we used a broader
panel consisting of 16 cytokines measured in plasma.
These include additional innate signals such as IL-1, 8,
12 and 15, as well as components of the IL-23/Th-17/
IL-17 axis [29,30]. Not only have we included both sexes
as in Skowera et al. (2004) [22], but we also compared
their cytokine signatures directly using a maximal exer-
cise paradigm to stimulate immune response for both
CFS and GWI. In addition to a direct comparison of in-
dividual cytokine levels, we constructed linear classifica-
tion models to identify characteristic cytokine subsets
for each group. We found a recurrent theme consisting
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activity, i.e. IL-23, IL-17, as significant contributors to
illness signature in both CFS and GWI across both sexes.
This was accompanied by contributions from IL-2, IL-4,
IL-10 and IL-12 in CFS and IL-5, IL-13, IL-15, IL-10 and
IFNγ in GWI, many of which were only observable under
challenge and during recovery. We submit that gender
and illness specific differences in Th-17 modulation may
constitute an important component of both CFS and
GWI. Importantly, confirmation of this result would re-
quire that male and female CFS and GWI subjects be con-
sidered 4 distinct groups for observational, mechanistic,
diagnostic, and treatment purposes.
Methods
Cohort and clinical assessment
As part of a larger ongoing study a subset of male and
female subjects diagnosed with CFS/ME (n = 12 male, n
= 10 female), GWI (n = 20 male, n = 10 female) and
healthy but sedentary Gulf War era veterans (n = 21
male, n = 9 female) were recruited from the Miami Vet-
erans Administration Medical Center. All subjects were
comparable in age, body mass index (BMI), ethnicity
and duration of illness. Subjects ranged in age between
30 and 55. Inclusion criteria for GWI was derived from
Fukuda et al. (1998) [2], and consisted in identifying vet-
erans deployed to the theater of operations between Au-
gust 8, 1990 and July 31, 1991, with one or more
symptoms present after 6 months from at least 2 of the
following: fatigue; mood and cognitive complaints; and
musculoskeletal complaints. Subjects were in good
health prior to 1990, and had no current exclusionary
diagnoses [31]. Medications that could have impacted
immune function were excluded as were supplements.
With regard to pesticides or herbicide exposure, this was
an urban population and we relied on GWI registry data
available to survey this aspect. The use of the Fukuda def-
inition in GWI is supported by Collins et al. (2002) [32].
Recruitment of CFS subjects was based on the case
definition of Fukuda et al. (1994) [33]. Exclusion criteria
for CFS included all of those listed in the current Cen-
ters for Disease Control (CDC) CFS case definition, in-
cluding the listed psychiatric exclusions, as clarified in
the International CFS Working Group [31]. All CFS sub-
jects were assessed for psychiatric diagnosis at the time
of recruitment with the Composite International Diag-
nostic Instrument (World Health Organization, 1997)
[34]. Based on this assessment, we excluded subjects
with DSM IV diagnoses for psychotic or melancholic de-
pression, panic attacks, substance dependency, or psych-
oses as well as any subjects currently suicidal. We also
excluded subjects with Borderline or Antisocial Person-
ality Disorder. Subjects had no history of heart disease,
COPD, malignancy, or other systemic disorders thatwould be exclusionary, as clarified by Reeves et al.
(2003) [31]. Importantly, care was taken to assess female
subjects at the same phase of the menstrual cycle,
namely in the follicular phase. This was self-reported by
subjects and based on time from end of last cycle. A
summary description of the subject subsets is listed in
Additional file 1: Table S1.
Exercise challenge
Immune response was stimulated with a standard
Graded eXercise Test (GXT) using a Vmax Spectra 29c
Cardiopulmonary Exercise Testing Instrument, Sensor-
Medics Ergoline 800 fully automated cycle ergometer,
and SensorMedics Marquette MAX 1 Sress ECG.
According to the McArdle protocol [35] subjects ped-
aled at an initial output of 60 watts for 2 minutes,
followed by an increase of 30 watts every 2 minutes until
the subject reached: 1) a plateau in maximal oxygen con-
sumption (VO2); 2) a respiratory exchange ratio >1.15;
or 3) the subject stopped the test. A first blood draw
was conducted prior to exercise following a 30-minute
rest. Second and third blood draws were conducted
upon reaching peak effort (VO2 max) and at 4-hours
post exercise respectively. Summary statistics describing
the exercise capacity in terms of the weight-adjusted
maximum VO2 measured in L/min/kg are presented for
each group in Additional file 1: Table S1. Results indi-
cate a decline in the average maximum VO2 achievable
with healthy controls performing best and CFS subjects
faring the worst. This trend achieved statistical signifi-
cance in the male subjects (p = 0.04) with healthy male
subjects performing better than both illness groups. In
light of this finding we suggest that results presented
here be interpreted as immune response at maximum
perceived exertion but not necessarily at equivalent exer-
cise intensity. We consider reduced exercise capacity to
be another symptom of GWI and CFS. The characteris-
tic immune response patterns measured at maximum
perceived exertion capture this implicitly as well as a
host of other more discriminating features of both
illnesses.
Ethics statement
All subjects signed an informed consent approved by the
Institutional Review Board of the University of Miami
and the Miami Veterans Affairs Medical Center. Ethics
review and approval for data analysis was also obtained
by the IRB of the University of Alberta.
Laboratory measurements
Plasma was separated within 2 hours of collection and
stored at −80°C until assayed. We measured 16 cyto-
kines in plasma using Quansys reagents and instrument
(Quansys Biosciences, Logan, Utah) in the same way as
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with unknown etiology and illness trigger [16,36]. The
Quansys Imager, driven by an 8.4 megapixel Canon
20D digital SLR camera, supports 96 well plate based
chemiluminescent imaging. The Q-Plex™ Human Cyto-
kine - Screen (16-plex) is a quantitative enzyme-linked
immunoabsorbent assay (ELISA)-based test, where six-
teen distinct capture antibodies have been absorbed to
each well of a 96-well plate in a defined array. The range
of the cytokine concentrations used in the standard cali-
bration samples were adjusted for each cytokine along
with sample exposure time to provide the most reliable
comparison possible of GWI and CFS patients with con-
trols across the range of cytokine concentrations known
and expected in plasma. We used a second order (k = 2)
polynomial regression model: Yp = b0 + b1X1 + b2X2.... +
bkXk, as a calibration curve, with intercept b0, regression
coefficients b1 to bk for each degree and where Yp was the
predicted concentration. The standard sample concentra-
tions used to establish these calibration curves for each
cytokine as well as the detection limits for this assay have
been described in detail in previous work by our group
[16]. In brief, these support an average coefficient of vari-
ability (CV) of 0.20 for inter-assay comparisons and a
value of 0.09 for intra-assay repeatability.
Statistical analyses
To assess the significance of differences in the mean ex-
pression of individual cytokines separating each subject
group we used a standard parametric t test after
performing a logarithmic (log2) transformation as well
as a non-parametric Wilcoxon ranksum test. The latter
was used as a confirmatory measure for the sake of com-
pleteness and to assess the adequacy of the log2 trans-
form in restoring normality to the distribution of values.
As an extension of this single-marker univariate analysis,
the use of cytokines in combination with one another
was also considered. This was done by constructing lin-
ear discriminant classification models that used multiple
cytokines in concert to distinguish individuals in each
group. Cytokines are highly co-expressed as a result of
the feedback and feed-forward regulatory mechanisms
they support [37]. Unfortunately traditional ordinary
least squares regression performs poorly when correlated
or collinear terms are used together due to variance in-
flation [38]. Two complementary methods were used to
address this issue and provide the most stable regression
models possible: the first is based on truncation of
highly correlated terms whereas the second is based on
the creation of cytokine constructs that are minimally
correlated. Based on truncation of terms, the stepwise
method mitigates the effect of cross-correlation between
cytokines by favoring the identification of subsets of cy-
tokines that are minimally redundant [39]. According tothis algorithm, model terms were selected sequentially
based on their respective partial-F test values. Cytokines
with a null probability p(partial F) < 0.05 were selected
for recruitment into the regression model while those
currently in the model but showing a revised p (partial
F) > 0.10 were removed. In the resulting model an ob-
served row x from the sample array is classified into
group I rather than group J if 0 < B0 + x*B, where the co-
efficient vector B and intercept vector B0 are estimated
from the data.
In some cases truncation of terms proved too severe
and the complementary approach of reconciling overlap-
ping expression patterns was used. For example, in the
case of female CFS subjects the constraint of minimal
colinearity, or redundancy between markers, that is im-
plicit to the stepwise algorithm resulted in poor classifier
performance. As a result, the effects of relaxing this con-
straint were explored using an all-possible-subsets selec-
tion method and a reconciliation of terms based on a
correction of covariance matrix structure. In this case
random subsets of 5 cytokines were selected from all 48
candidate biomarkers (16 cytokines at 3 time points)
and evaluated using a linear classification model as de-
scribed above. This was repeated over 500 iterations. In-
dividual cytokines were then ranked according to the
frequency with which they were selected in classification
models that supported an assignment accuracy of at
least 80%. In each candidate model deviations from mu-
tual independence between markers was corrected using
a diagonal covariance matrix estimate [40].
All cytokine concentrations were log2 transformed
and normalized to have a mean value of 0 and a variance
of 1.0. Missing values were imputed using a non-zero
value of 0.0001 in order to make maximal use of all pro-
files in the regression calculations. Leave-one-out cross
validation was used as a measure of the predictive stabil-
ity of each model. According to this strategy class as-
signments for each subject are performed based on
models constructed in the absence of that particular
subject’s cytokine profile. All classifiers were evaluated
based on their leave-one-out cross-validation perform-
ance rather than their ability to fit the training data. Per-
formance measures used include overall accuracy
(correctly classified samples / total classified samples) in
assigning subjects to their proper diagnostic group, sen-
sitivity (correctly classified positive / true positive sam-
ples), specificity (correctly classified negative / true
negative samples), positive predictive (correctly classified
positive / positive classified samples) and negative pre-
dictive (correctly classified negative / negative classified
samples) values.
All calculations described above were performed using
the SPSS Statistics software platform version 19 (IBM,
SPSS Inc., Chicago, IL) as well as the classify, classperf,
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tics Toolbox and the MatLab Bioinformatics Toolbox
(The MathWorks, Inc., Natick, MA).
Results
Gender-specific differences in immune signatures among
healthy controls
In order to assess the importance of sex-specific im-
mune response to exercise a comparison of cytokine ex-
pression profiles in male and female subjects was
conducted in the healthy control group. In a first ana-
lysis, the log 2 transformed expression levels of individ-
ual cytokines were compared using a standard t test and
a non-parametric Wilcoxon test at each phase of exer-
cise. Results presented in Additional file 1: Table S2
show significant differences in cytokine expression
across sexes, namely elevated IL-23 in healthy female
subjects at all time points (p ≤ 0.01) as well as elevated
IL-12 expression post-exercise (p = 0.03). A trend to-
wards higher IL-5 levels at peak effort in male subjects
(p = 0.08) was also observed but this did not achieve
statistical significance. Cytokines such as these are not
expressed independently of one another but instead their
patterns arise as a result of one or several basic immune
processes acting in concert. In an attempt to explore
concurrent immune processes a step-wise variable selec-









mHC vs fHC at T0 Il-2 T0 −0.81 19 2 21
Il-23 T0 1.14 2 7 9
mHC vs fHC at T0-T2 Il-2 T1 −0.72 19 2 21
Il-5 T1 −0.59 1 8 9
Il-23 T0 1.24
CFS
mCFS vs fCFS at T0 Il-8 T0 1.00 7 5 12
2 8 10
mCFS vs fCFS at T0-T2 TNFb T2 −0.91 8 4 12
Il-6 T1 −0.83 1 9 10
Il-8 T0 1.75
GWI
mGWI vs fGWI at T0 NA
mGWI vs fGWI at T0-T2 Il-2 T2 −1.51 19 1 20




Performance values correspond to leave-one-out cross validation results.which acting in combination might further support the
separation of male and female subjects in both illness
and healthy control groups. The results of this modeling
only emphasized the importance of the immunological
differences between sexes.
The performance of classification models separating
male from female subjects within the healthy control,
CFS and GWI groups respectively is summarized in
Table 1 (Figure 1). Results indicate that male and female
subjects in the healthy control group can be readily dis-
tinguished at rest (T0) by as few as 2 cytokines, namely
IL-2 and IL-23, with a specificity of 78% and sensitivity
of 90%. The use of an exercise challenge only improves
upon this, with levels of IL-23 at rest (T0) in combin-
ation with IL-2 and IL-5 at peak effort supporting 89%
specificity with 90% sensitivity. Differences in cytokine
profile between the sexes remain significant in both
GWI and CFS but with somewhat lower specificity in
GWI (70%) and sensitivity in CFS (67%). Of particular
interest, no cytokines out of the 16 measured could dis-
tinguish between the sexes in GWI subjects at rest.
Only under exercise challenge could male GWI subjects
be distinguished from their female counterparts on the
basis of cytokine expression. Collectively these differ-
ences in immune response to exercise strongly support
a stratification of the cohort on the basis of sex prior to
any analysis of illness-specific cytokine signatures.ale subjects within each diagnostic group
al Accuracy NPV PPV Specificity Sensitivity
True male 0.87 0.90 0.78 0.90 0.78
True Female
True male 0.90 0.95 0.80 0.90 0.89
True Female
True male 0.68 0.78 0.62 0.58 0.80
True Female
True male 0.77 0.89 0.69 0.67 0.90
True Female
NA NA NA NA NA
True male 0.87 0.86 0.88 0.95 0.70
True Female
Figure 1 Gender differences in immune signatures among healthy controls. Immune cytokine expression of male and female healthy
controls was compared using a step-wise method across all time points (rest, peak activity, and recovery). Red arrows indicate a negative
contribution of a particular cytokine in female healthy controls compared to males and vice versa for black arrows. Arrow line thickness is
proportional to the magnitude of the standardized canonical coefficients. Changes in IL-23 were a dominant factor at all time points, in particular
when cast against concurrent levels of IL-2 and IL-5 expression under challenge.
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Once again the expression levels of individual cytokines
were compared using the standard t and Wilcoxon
ranksum tests. Results are presented for male subjects in
Additional file 1: Table S3. These suggest that levels of
IL-8 and IL-13 (p = 0.04, 0.03) were significantly elevated
in male GWI subjects at rest, however this was not sup-
ported by the Wilcoxon test. In contrast, both paramet-
ric and non-parametric tests indicate that male CFS
subjects expressed significantly higher levels of IL-2;
both at peak effort and at 4 hours post exercise (p = 0.03,
0.02). These subjects also expressed significantly higher
levels of IL-23 both prior to and following exercise
(p = 0.01, 0.01) but not at peak effort. Using the same ap-
proach as before, cytokine subsets were identified that best
supported a linear model for the classification of male sub-
jects at each phase of exercise as well as over the entire
challenge. These results are described in Table 2 (Figure 2).
While healthy male subjects could be distinguished from
male GWI subjects at rest (T0) and during recovery (T2),
these groups could not be distinguished on the basis of
cytokine signatures at peak activity (T1). At rest (T0), dif-
ferences in IL-13 in male GWI subjects were best consid-
ered in the context of IL10, and IL-23, two cytokines that
did not differ significantly in expression level. Used to-
gether as an illness signature for GWI this combination of
cytokines delivered a predicted specificity of 76% and a
sensitivity of 70% (PPV = 74%; NPV = 73%) in a leave-one
-out cross-validation scenario. At recovery (T2), the classi-
fication of male GWI subjects was again supported by ex-
pression of IL-13 in the context of IL-10 and IL-23. Levels
of IL-1b expression also contributed significantly in pro-
viding a contextual basis for changes in IL-13. These four
cytokines used in combination supported higher sensitivity
(80%) than the model identified at rest but with a some-
what lower specificity (67%) (PPV = 70%; NPV = 78%).
When aggregating cytokine profiles across all three time
points the subset of IL-13, 10 and 23 measured at rest
were again retained and additional context was recruitedin the form IFN-γ at peak effort and IL-15 post-exercise.
Used together, these cytokines measured across all
three phases of exercise delivered a sensitivity of 85%
and a specificity of 81% in cross-validation (PPV = 81%;
NPV = 85%).
Using a similar approach we attempted to isolate a
characteristic subset of cytokines in the smaller illness
group of male CFS subjects. Reflecting a shared trend
with GWI, a linear classification model based solely on
IL-23 levels at rest distinguished between male CFS and
control subjects with a predicted classification sensitivity
of 75% and a specificity of 76% in leave-one-out cross-
validation. Though false negative predictions were lim-
ited (NPV = 84%), use of this marker alone produced a
high number of false positive assignments (PPV = 64%).
An identical model was identified in the recovery phase
with very similar classification performance. At peak ef-
fort, differences in IL-2 expression were cast in the rela-
tive context of concurrent levels of IL-6, 10 and 15.
Taken together these produced a predicted classification
sensitivity of 92% but specificity remained unchanged at
76%. Accordingly the negative predictive value improved
(NPV = 94%) but only marginal change in positive pre-
dictive rate was produced (PPV = 69%). Only by account-
ing for all exercise phases was it possible to produce a
more balanced classification performance. Using IL-2,
10, 12 and 23 measured selectively at rest (T1) and post-
exercise (T2) noticeably improved the classification per-
formance albeit in a small subject group (sensitivity = 83%;
specificity = 86%; PPV = 77%; NPV = 90%). This empha-
sized the importance of an exercise paradigm in investigat-
ing CFS in particular. Common to both GWI and CFS
illness signatures were the direct or indirect contributions
of IL-10 and IL-23 expression though these occurred at
very different times. While levels measured at rest sup-
ported an illness signature in GWI, their impact in CFS
was only observable during and after exercise, again em-
phasizing the importance of a challenge and response
timeline in distinguishing these illnesses.







Total Accuracy NPV PPV Specificity Sensitivity
Male GWI Subjects
GWI vs HC males at T0 Il-10 T0 −1.32 16 5 21 True HC male 0.73 0.73 0.74 0.76 0.70
Il-13 T0 1.23 6 14 20 True GWI male
Il-23 T0 0.53
GWI vs HC males at T1 NA True HC male NA NA NA NA NA
True GWI male
GWI vs HC males at T2 Il-1b T2 −0.59 14 7 21 True HC male 0.73 0.78 0.70 0.67 0.80
Il-10 T2 −1.10 4 16 20 True GWI male
Il-13 T2 1.02
Il-23 T2 0.62
GWI vs HC males at T0-T2 Il-15 T2 −0.64 17 4 21 True HC male 0.83 0.85 0.81 0.81 0.85





CFS vs HC males at T0 Il-23 T0 1.00 16 5 21 True HC male 0.76 0.84 0.64 0.76 0.75
3 9 12 True CFS male
CFS vs HC males at T1 Il-2 T1 1.84 16 5 21 True HC male 0.82 0.94 0.69 0.76 0.92
Il-6 T1 −0.66 1 11 12 True CFS male
Il-10 T1 −0.75
Il-15 T1 −0.66
CFS vs HC males at T2 Il-23 T2 1.00 16 5 21 True HC male 0.73 0.80 0.62 0.76 0.67
4 8 12 True CFS male
CFS vs HC males at T0-T2 Il-2 T2 0.99 18 3 21 True HC male 0.85 0.90 0.77 0.86 0.83




Performance values correspond to leave-one-out cross validation results.
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In a similar analysis of female subjects we were unable
to identify any cytokines that, when measured at rest,
supported a characteristic signature for GWI. As in their
male counterparts, levels of IL-8 were significantly ele-
vated in female GWI subjects. However unlike the
former, this was only detectable at peak effort (T1)
(p = 0.04) as were elevated levels of IL-5 (p = 0.03)
(Additional file 1: Table S4). Also found were significantly
lower levels of IL-23 at recovery (T2) (p = 0.03). This cyto-
kine was only marginally increased in male subjects at the
same phase of exercise (Additional file 1: Table S3). Levels
of IL-1a measured at recovery, and IL-10 measured at
peak effort, were also found significantly lower in
GWI female subjects based on the Wilcoxon ranksumtest (p = 0.02, 0.03). Identification of a linear classification
model for female GWI subjects cast increased IL-5 ex-
pression in the context of IL-17 levels at peak effort (T1).
Used in combination these two cytokines measured at
peak effort supported classification of female GWI relative
to control subjects with a sensitivity of 80% and a specifi-
city of 89% (PPV = 89%; NPV = 80%) in cross-validation,
albeit in a smaller pilot cohort (n = 10). At recovery, the
significantly lower expression of IL-23 alone was sufficient
to distinguish female GWI from control with a predicted
classification sensitivity of 70% and a specificity of 89%
(PPV = 88%; NPV = 73%). This did not improve noticeably
when allowing the selection of IL-5 at peak effort and IL-
23 post-exercise from all phases of exercise (Figure 3). It is
interesting to note that contrary to the models identified
Figure 2 Cytokine signatures separating illness groups in male subjects. Immune cytokine expression patterns separating of male GWI, CFS
and healthy control subjects identified using a step-wise selection method across all time points (rest, peak activity, and recovery). Red arrows
indicate a negative contribution, vice versa for black arrows. Arrow line thickness is proportional to the magnitude of standardized canonical
coefficients. NK cell promoters (IL-12 or 15) are observed in both illnesses, as are IL-10 and 23. Stronger IL-2 expression was characteristic of CFS
while stronger IL-13 contribution was indicative of GWI (Table 2 and Additional file 2: Table S5).
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textual markers in the classification models for female
subjects. Indeed, only those cytokines showing significant
differences in expression were selected.
In comparison, it was very difficult to find any strong
differences in cytokine expression separating female CFS
subjects from healthy control. Indeed, only decreased
expression of IL-4 (p = 0.02) and increased expression of
IL-1a (Wilcoxon p = 0.04) measured at peak effort in fe-
male CFS subjects reached statistical significance in this
data (Additional file 1: Table S4). Nor did casting this
difference in the context of other cytokines create a
more robust illness signature. In all classification
models, very high false positive rates were produced in
leave-one-out cross-validation regardless of the time
point considered (Table 3). Positive predictive values were
less than 65% with specificity values below 50%. It is im-
portant to remember that stepwise selection applies strict
constraints to encourage the recruitment of mutually in-
dependent markers. In an alternative approach, we applied
an all-possible-subsets selection with a multivariate cor-
rection to relax this constraint and allow the inclusion of
cytokines that might be more closely co-expressed. This
more exhaustive search identified IL-17 at peak effort (T1)
and IL-10 during recovery (T2) as two of the most fre-
quently selected markers in 500 random subsets of 5 cyto-
kines. Using these two markers together and applying a
canonical correction for co-expression supported aclassification specificity of 89%, at a sensitivity of 70%
(PPV of 88%) (Table 3). Inclusion of IL-5 measured at T2,
the third ranking marker, supported a complete separation
of female CFS subjects from their healthy counterparts. An
examination of the correlation structure confirmed that
expression of IL-10 at T2 and IL-17 at T1 and T2 were sig-
nificantly correlated (p = 0.04, 0.05) making them undesir-
able candidates in the initial stepwise selection scheme.
When comparing female GWI and CFS immune sig-
natures directly, highly significant differences were ob-
served at all three time points. Significantly lower levels
of IL-4 (p = 0.04, 0.02, 0.01) and IL-8 (p = 0.02, 0.00,
0.01) were observed in female CFS subjects compared to
their GWI counterparts at all three phases of exercise.
Similarly decreased levels of IL-5 were observed at rest
and peak effort in CFS compared to GWI in female sub-
jects (p = 0.01, 0.01). Lower levels of TNFα were also
found during recovery using the ranksum test (p = 0.02).
These same cytokines were expressed at intermediate
levels in healthy control subjects suggesting a reversal of
polarity in expression profile for CFS compared to GWI
in female subjects only. In keeping with these differ-
ences, female GWI and CFS groups separated almost
perfectly on the basis of IL-5 and IL-1b levels alone
measured at rest (Additional file 2: Table S5). This pat-
tern of opposites was not observed in male subjects
where cytokine levels in CFS and GWI typically trended
in the same direction in comparison to control. As a
Figure 3 Cytokine signatures separating illness groups in female subjects. Immune cytokine expression patterns separating of female GWI,
CFS and healthy control subjects identified using a step-wise selection method across all time points (rest, peak activity, and recovery). Red
arrows indicate a negative contribution, vice versa for black arrows. Arrow line thickness is proportional to the magnitude of standardized
canonical coefficients. While decreased IL-23 expression in the context of increased IL-5 levels provided strong separation of GWI from healthy
controls the signal for CFS was much weaker and required relaxation of the constraints on cross-correlation between cytokines.
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requirement of mutual independence was relaxed. In-
deed when allowing for selection and reconciliation of
IL-1β and TNFβ co-expression at rest, two highly corre-
lated markers (r = 0.81, p < 0.01 in CFS), we obtained an
assignment accuracy of 66% for male GWI versus male
CFS subjects. These groups separated almost completely
with the addition of IL-2 and IL-6 co-expression at peak
effort (Additional file 2: Table S5).
Discussion
GWI and CFS remain poorly understood illnesses with
complex etiology. Though they show considerable overlap
in clinical presentation there is mounting evidence
supporting the involvement of characteristic immune and
endocrine dysfunction in each illness. In this work we
compared these sister illnesses and their cytokine expres-
sion profiles in both male and female subjects separately
to explore the role of endocrine-mediated modulation of
immune response. As persistent and disabling fatigue is a
key presenting symptom in both illnesses, a graded exer-
cise challenge was used to stimulate immune response
and amplify cytokine expression in a clinically relevant
way. Several cytokines are recognized as exercise-
responsive or metabolically active in healthy individuals.These myokines include IL-1ra, 6, 8, 10, 15 and TNF-α
[41,42]. In this work IL-10 and IL-15 appear as illness
markers in male subjects with expression levels suggesting
a delayed or compromised anti-inflammatory response to
exercise. The same would appear true of exercise response
in female CFS subjects. Interestingly significant differences
in the immune response to exercise between male and fe-
male populations were immediately observed even in the
healthy control group. Healthy female subjects could be
distinguished from their male counterparts by significantly
elevated expression of IL-12 and IL-23. While male GWI
subjects could be distinguished from control on the basis
of cytokine expression at rest but not at peak effort, the
opposite was true for female subjects. Moreover, female
GWI and CFS subjects could be separated almost perfectly
on the basis of IL-1b and IL-5 levels alone, albeit in a
small pilot cohort (n = 10). Indeed, cytokine expression
would typically trend lower than control in female CFS
and higher than control in female GWI, reaching statis-
tical significance for levels of IL-4, 5 and 8. In contrast,
male GWI could not be distinguished easily from their
CFS counterparts on the basis of minimally overlapping
cytokine markers as these typically trended in the same
direction compared to control. Separation of these sub-
jects was achieved in previous work by our group [28] but







Total Accuracy NPV PPV Specificity Sensitivity
Female GWI Subjects
GWI vs HC females at T0 NA True HC female NA NA NA NA NA
True GWI female
GWI vs HC females at T1 Il-5 T1 1.20 8 1 9 True HC female 0.84 0.80 0.89 0.89 0.80
Il-17 T1 −1.03 2 8 10 True GWI female
GWI vs HC females at T2 Il-23 T2 −1.00 8 1 9 True HC female 0.79 0.73 0.88 0.89 0.70
3 7 10 True GWI female
GWI vs HC females at T0-T2 Il-23 T2 −1.00 8 1 9 True HC female 0.84 0.80 0.89 0.89 0.80
Il-5 T1 0.99 2 8 10 True GWI female
Female CFS Subjects
CFS vs HC females at T0 Il-4 T0 −0.84 5 4 9 True HC female 0.74 0.83 0.69 0.56 0.90
Il-17 T0 0.77 1 9 10 True CFS female
CFS vs HC females at T1 Il-2 T1 −1.00 4 5 9 True HC female 0.63 0.67 0.62 0.44 0.80
2 8 10 True CFS female
CFS vs HC females at T2 Il-2 T2 −1.00 3 6 9 True HC female 0.68 1.00 0.63 0.33 1.00
0 10 10 True CFS female
CFS vs HC females at T0-T2 Il-2 T1 −1.00 4 5 9 True HC female 0.68 0.80 0.64 0.44 0.90
1 9 10 True CFS female
** All possible subsets
CFS vs HC females at T0-T2 IL-17_T1 1.00 8 1 9 True HC female 0.79 0.73 0.88 0.89 0.70
IL-10_T2 −1.68 3 7 10 True CFS female
Performance values correspond to leave-one-out cross validation results.
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sured in supernatants isolated and treated in vitro with the
mitogen phytohaemagglutinin (PHA), a stimulant of T cell
activity. The current work would suggest these groups
may share several features of cytokine co-expression in
plasma and that the patterns and levels obtained in re-
sponse to in vitro stimulation with a specific mitogen may
be required to provide the resolution necessary to distin-
guish one set from the other unequivocally. Moreover, as
in this previous analysis it may also be necessary to recon-
cile partially correlated cytokines and use these in con-
junction with one another instead of truncating in order
to converge on a set of minimally overlapping cytokines.
This observation was further confirmed in our analysis of
female CFS subjects. Separation of these subjects from
healthy control improved dramatically when the require-
ment for mutual independence was relaxed and statistical
corrections were made to include and reconcile the co-
expressed markers IL-17 at peak effort and IL-10 at recov-
ery. Likewise male CFS and GWI subjects could be
separated almost completely when adjusting for the co-
expression of TNFβ, IL-1β, 2 and 6 at rest and peak effort.
These differences not withstanding, in looking across
all subject groups we found a recurrent theme consisting
of cytokines directly or indirectly involved with Th17 ac-
tivity [30]. For example, IL-23 was a distinguishingfeature of sex in healthy subjects. It was also a significant
contributor to illness signature in both CFS and GWI,
along with IL-17 across both sexes. In one subset or an-
other, this was accompanied by contributions from IL-
1b, IL-2 and IFNγ among others. In addition IL-6 and
IL-8 contributed to differences between male and female
subjects within each illness group. It is interesting to
note that most of these cytokines were not differentially
expressed across groups even though they contributed
significantly to the classification of these subjects. IL-1, 6
and 23 are known inducers of Th17 response, which in
turn is a producer of IFNγ [30]. Conversely IL-2 is gen-
erally known as a Th17 antagonist [43]. Indeed the ex-
pression of these cytokines is not as disparate as it may
seem. For example, Liu et al. (2007) [44] describe a
mechanism by which IL-1 induces the production of
IL-23 via NF-kappa B activation, which in turn pro-
motes the production of IL-6 and 8 in human
fibroblast-like synoviocytes from rheumatoid arthritis
patients. IL-10 was also selected across illnesses, par-
ticularly in male subjects, as an important contextual
element for IL-23 expression. Work by Verreck et al.
(2004) [29] has implicated the interplay between IL-23-
producing type 1 macrophages and IL-10-producing
type 2 macrophages in modulating immune response
to mycobacteria.
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contribution (along with family member IL-12) as a
marker of gender-specific response to exercise suggests
significant involvement of the sex hormone axis in
modulating the IL-23/Th17/IL-17 immune response. For
example there is evidence that progesterone may sup-
press Th1 and Th17 pathway activity and induce an
anti-inflammatory response when present at pregnancy
levels [45]. Conversely progesterone has been shown to
enhance Th2 and T regulatory (Treg) responses. In the
current analysis the appearance of IL-4 and IL-5 as
markers of GWI and CFS in the female subset further
supports possible involvement of a sex hormones in
modulating the balance between Th2 and Th17 re-
sponse. Studies in human cell cultures and in mice have
shown that human T cells exhibit a sex-specific differ-
ence in the production of IFNγ and IL-17 driven by an-
drogen status and possibly the expression of peroxisome
proliferator activated receptors PPARα and PPARγ [46].
In fact, in animal models the disappearance of normal
sex-driven differences in the gene regulatory network
modulating Th17 immune response has been implicated
recently in supporting an increased susceptibility to
rheumatoid arthritis (RA) [47]. Collectively these works
and the analysis presented here suggest that imbalance
in the sex hormone regulation of Th17 immune re-
sponse may be a shared component of these illnesses.
In GWI specifically, recent work has pointed to dis-
ruption of normal cholinergic regulation of immune
function as a possible result of exposure to battlefield
agents [48,49]. For example, mRNA levels of cytokines
IL-6, IL-17 and IL-13 among others have been shown to
respond readily to organophosphate exposure [50].
Acetylcholine (ACh) is known to regulate T cell function
by acting on the nicotinic (nAChR) and muscarinic
(mAChRs) cholinergic receptors [51]. In recent work,
Qian et al. (2011) [52] demonstrated in culture that
nicotinergic stimulation of CD4+/CD62L(L-selectin) + T
cells upregulated IFNγ and down-regulated IL-17 secre-
tion, whereas the muscarinic stimulation enhanced IL-
10 and IL-17 while inhibiting INFγ secretion. Muscarinic
acetylcholine signaling has also been found to promote
IL-8 release via PKC, ERK1/2 and NF-ΚB pathways [53].
Similarly nicotinic receptor (nAChR) antagonists, ERK1/
2 inhibitors or intracellular calcium chelators reduced
IL-8 secretion by human epithelial cells [54]. Based on
this finding, persistent cholinergic stimulation would
support the increased levels of IL-8 observed here in
both male and female GWI subjects. Increased
nicotanergic activation would support an ACh-driven
down-regulation of Th17 response evidenced by de-
creased IL-23 in female GWI subjects. Elevated IL-5
levels in this group would further support the suppres-
sion of IL-17 response as part of a sex hormonemediated shift towards a Th2 status. The absence of this
added sex-specific driver of Th2 polarization might ex-
plain the more subdued trend towards Th17 suppression
observed in male GWI subjects. It is important to note
that the above-mentioned mechanisms were typically stud-
ied under specific experimental conditions whereas the
immune signatures reported in this work were obtained in
whole blood from human subjects. In order to obtain a
more detailed understanding of the precise mechanisms
that underlie these cytokine profiles it will be important to
cast these in the context of the corresponding immune cell
demographics using flow cytometric methods [55].
Though with some illness-specific variations, a continued
trend away from Th2 polarity is observed in male CFS sub-
jects with these subjects showing considerable overlap in
cytokine expression with their GWI counterparts. We also
found a decrease in Th2 polarity when comparing levels of
IL-4 and IL-5 in female CFS with those in female GWI. In
our earlier work with a much larger cohort of female CFS
subjects (n = 40; mean age 53 ± 1.8 years) [16], we had
found elevated levels of Th2 markers in female CFS sub-
jects when compared to healthy controls. As discussed
above, a potentially important contributor to this may be
menopausal status since sex hormones can be important
modulators of Th2 polarization [45,56] and age has been
shown to be an important contributor to increased IFNγ
response in women [57]. In comparison, the opposite trend
in IFNγ response with age is typically true in men and oc-
curs over a more narrow range. It is important to note
therefore that this previous work with female CFS subjects
was biased towards a post-menopausal population (n = 40;
mean age 53 ± 1.8) whereas the smaller cohort used in this
analysis would be more adequately described as peri-
menopausal (n = 10; mean age 43 ± 2.8). Indeed when we
compared healthy control groups across these studies we
found significantly lower expression of IL-4 in the older
control group (p = 0.003) while IL-4 levels in both the
older and younger CFS groups were comparable (p = 0.49)
(Additional file 3: Figure S1). Certainly the reduced size of
the current cohort, in particular the number of female
subjects, may have limited the statistical resolution for
detecting differences in the expression levels of individual
cytokines. However, the compatibility of healthy control
groups should almost certainly be considered when com-
paring immune signatures across studies especially in
women, as these control populations constitute a moving
endocrine-immune benchmark. In addition to sex hor-
mones, stress and growth hormones produced along the
hypothalamic-pituitary-adrenal (HPA) and hypothalamic-
pituitary-thyroidal (HPT) axes are also important immune
modulators [58,59]. Moreover, dysfunction of these axes
has also been documented in these illnesses [6,60]. Al-
though in this study the immune-modulatory effects of
these hormones were implicit to the cytokine signatures,
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plained variations in immune signature and potentially im-
prove the resolution of a diagnostic panel for these illnesses.
These limitations notwithstanding, certain preliminary
observations regarding the immune processes involved in
these illnesses may still be made. In particular, it was in-
teresting to note that the IL-23/Th17/IL-17 axis appears
differentially modulated across sexes in healthy individuals
and that different markers of this same axis appear to
contribute to the delineation of GWI and CFS in a sex
and illness-specific way. Our work across multiple cohorts
has shown this theme of Th17 dysfunction to be highly
conserved even though individual markers may not be.
This work also suggests that more robust cytokine signa-
tures may be obtained by accounting for sex-specific dif-
ferences in endocrine-immune crosstalk and that future
studies should consider male and female CFS and GWI
subjects as 4 distinct groups for observational, mechanis-
tic, diagnostic, and potentially treatment purposes as well.
Conclusions
In summary even though additional study in larger co-
horts is needed to further substantiate the diagnostic po-
tential of these individual biomarkers, certain themes
emerge nonetheless. In particular, we consistently found
the expression of cytokines directly or indirectly in-
volved with Th17 activity as significant contributors to
illness signature in both CFS and GWI, across both
sexes. However, trends in expression levels relative to
control subjects varied between groups, as did the
choice of additional markers. These trends were more
subtle and co-expression patterns more tightly inte-
grated in CFS, in particular in female subjects. In
addition, while male GWI subjects could be distin-
guished at rest but not at peak effort, the opposite was
true for female subjects. These observations further
reinforce the need for stratification according to gender
as well as the importance of an exercise challenge in
these studies. Indeed, a comparison with our previous
study of another CFS cohort suggested that female sub-
jects should be stratified further with respect to age and
menopausal status. This observation together with the
gender differences found in this work support an import-
ant role for endocrine modulation of immunity in these
illnesses and argue in favor of stratification of cohorts into
separate groups in each illness according to sex.
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